| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 68 | 2023 | 314 | 15.120 |
Why?
|
| Gait | 87 | 2023 | 195 | 14.040 |
Why?
|
| Gait Disorders, Neurologic | 38 | 2022 | 67 | 10.300 |
Why?
|
| Walking | 53 | 2023 | 108 | 7.830 |
Why?
|
| Accidental Falls | 30 | 2022 | 39 | 6.890 |
Why?
|
| Postural Balance | 28 | 2022 | 62 | 5.030 |
Why?
|
| Aged | 102 | 2023 | 4000 | 3.480 |
Why?
|
| Humans | 157 | 2023 | 12240 | 3.290 |
Why?
|
| Cognition | 24 | 2022 | 641 | 2.880 |
Why?
|
| Male | 101 | 2023 | 6815 | 2.740 |
Why?
|
| Psychomotor Performance | 16 | 2020 | 85 | 2.670 |
Why?
|
| Female | 101 | 2023 | 6974 | 2.660 |
Why?
|
| Aging | 23 | 2023 | 680 | 2.500 |
Why?
|
| Monitoring, Physiologic | 6 | 2020 | 35 | 2.490 |
Why?
|
| Wearable Electronic Devices | 8 | 2023 | 21 | 2.270 |
Why?
|
| Attention | 15 | 2020 | 46 | 2.260 |
Why?
|
| Aged, 80 and over | 52 | 2023 | 2152 | 2.220 |
Why?
|
| Accelerometry | 12 | 2019 | 48 | 2.040 |
Why?
|
| Brain | 9 | 2020 | 707 | 1.690 |
Why?
|
| Middle Aged | 47 | 2022 | 4043 | 1.690 |
Why?
|
| Exercise Therapy | 8 | 2023 | 42 | 1.560 |
Why?
|
| Transcranial Direct Current Stimulation | 3 | 2022 | 5 | 1.360 |
Why?
|
| Geriatric Assessment | 10 | 2018 | 96 | 1.310 |
Why?
|
| Neuropsychological Tests | 17 | 2020 | 558 | 1.290 |
Why?
|
| Cognition Disorders | 7 | 2019 | 437 | 1.270 |
Why?
|
| Reaction Time | 8 | 2019 | 53 | 1.220 |
Why?
|
| Physical Therapy Modalities | 7 | 2023 | 31 | 1.210 |
Why?
|
| Activities of Daily Living | 10 | 2023 | 182 | 1.200 |
Why?
|
| Executive Function | 9 | 2022 | 47 | 1.170 |
Why?
|
| Cross-Sectional Studies | 16 | 2022 | 400 | 1.110 |
Why?
|
| Adult | 33 | 2021 | 3557 | 1.100 |
Why?
|
| Motor Activity | 8 | 2018 | 175 | 1.100 |
Why?
|
| Prefrontal Cortex | 7 | 2023 | 66 | 1.040 |
Why?
|
| Movement | 8 | 2020 | 58 | 0.960 |
Why?
|
| Electric Stimulation Therapy | 4 | 2009 | 18 | 0.930 |
Why?
|
| Orthotic Devices | 4 | 2009 | 16 | 0.920 |
Why?
|
| Functional Laterality | 4 | 2014 | 21 | 0.850 |
Why?
|
| Task Performance and Analysis | 6 | 2016 | 27 | 0.830 |
Why?
|
| Methylphenidate | 6 | 2009 | 8 | 0.800 |
Why?
|
| Mobility Limitation | 7 | 2020 | 36 | 0.790 |
Why?
|
| Machine Learning | 5 | 2023 | 31 | 0.790 |
Why?
|
| Central Nervous System Stimulants | 6 | 2009 | 29 | 0.780 |
Why?
|
| Algorithms | 7 | 2017 | 169 | 0.770 |
Why?
|
| Gait Ataxia | 3 | 2013 | 5 | 0.760 |
Why?
|
| Exercise Test | 10 | 2023 | 62 | 0.760 |
Why?
|
| Periodicity | 3 | 2008 | 4 | 0.730 |
Why?
|
| Risk Assessment | 8 | 2022 | 295 | 0.710 |
Why?
|
| Deep Brain Stimulation | 2 | 2013 | 15 | 0.680 |
Why?
|
| Quality of Life | 8 | 2022 | 261 | 0.660 |
Why?
|
| Case-Control Studies | 11 | 2019 | 256 | 0.660 |
Why?
|
| Brain Mapping | 5 | 2020 | 59 | 0.650 |
Why?
|
| Young Adult | 11 | 2022 | 863 | 0.640 |
Why?
|
| Levodopa | 6 | 2020 | 14 | 0.630 |
Why?
|
| Tremor | 4 | 2020 | 60 | 0.620 |
Why?
|
| Heart Rate | 11 | 2010 | 55 | 0.620 |
Why?
|
| Martial Arts | 1 | 2020 | 1 | 0.620 |
Why?
|
| Swimming | 1 | 2020 | 4 | 0.620 |
Why?
|
| Biomechanical Phenomena | 10 | 2020 | 297 | 0.620 |
Why?
|
| Frontal Lobe | 3 | 2018 | 32 | 0.610 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2021 | 464 | 0.600 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 58 | 0.600 |
Why?
|
| Sensation Disorders | 2 | 2013 | 8 | 0.600 |
Why?
|
| Cognitive Dysfunction | 3 | 2022 | 449 | 0.590 |
Why?
|
| Antiparkinson Agents | 6 | 2013 | 18 | 0.590 |
Why?
|
| Time Factors | 11 | 2019 | 695 | 0.590 |
Why?
|
| Disability Evaluation | 3 | 2019 | 105 | 0.590 |
Why?
|
| Torso | 2 | 2016 | 2 | 0.580 |
Why?
|
| Pilot Projects | 9 | 2022 | 214 | 0.580 |
Why?
|
| Nerve Net | 2 | 2016 | 22 | 0.580 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 3 | 2007 | 19 | 0.570 |
Why?
|
| Alzheimer Disease | 5 | 2023 | 800 | 0.570 |
Why?
|
| Paresis | 2 | 2009 | 6 | 0.560 |
Why?
|
| Disabled Persons | 2 | 2023 | 47 | 0.560 |
Why?
|
| Severity of Illness Index | 8 | 2022 | 423 | 0.550 |
Why?
|
| Fractals | 5 | 2017 | 11 | 0.540 |
Why?
|
| Exercise | 7 | 2023 | 233 | 0.520 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2017 | 8 | 0.510 |
Why?
|
| Risk Factors | 13 | 2019 | 1049 | 0.510 |
Why?
|
| Walking Speed | 4 | 2023 | 13 | 0.490 |
Why?
|
| Learning | 2 | 2014 | 34 | 0.490 |
Why?
|
| Blood Pressure | 6 | 2020 | 99 | 0.490 |
Why?
|
| Independent Living | 7 | 2022 | 137 | 0.480 |
Why?
|
| Medical Informatics Applications | 1 | 2015 | 1 | 0.460 |
Why?
|
| Biomedical Engineering | 1 | 2015 | 4 | 0.460 |
Why?
|
| Subthalamic Nucleus | 2 | 2013 | 7 | 0.460 |
Why?
|
| Self Report | 3 | 2022 | 94 | 0.450 |
Why?
|
| Treatment Outcome | 9 | 2018 | 1478 | 0.450 |
Why?
|
| Stroke | 2 | 2022 | 117 | 0.430 |
Why?
|
| Hypokinesia | 4 | 2020 | 8 | 0.420 |
Why?
|
| Nerve Fibers, Unmyelinated | 1 | 2013 | 1 | 0.400 |
Why?
|
| Telemetry | 1 | 2013 | 5 | 0.400 |
Why?
|
| Reproducibility of Results | 8 | 2019 | 324 | 0.390 |
Why?
|
| Cross-Over Studies | 3 | 2022 | 24 | 0.380 |
Why?
|
| Myelin Sheath | 1 | 2013 | 11 | 0.380 |
Why?
|
| Hypertension | 4 | 2020 | 85 | 0.370 |
Why?
|
| Huntington Disease | 3 | 2022 | 29 | 0.370 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 726 | 0.360 |
Why?
|
| Multiple Sclerosis | 2 | 2021 | 32 | 0.340 |
Why?
|
| Monitoring, Ambulatory | 3 | 2017 | 10 | 0.340 |
Why?
|
| User-Computer Interface | 1 | 2010 | 7 | 0.330 |
Why?
|
| Freezing Reaction, Cataleptic | 1 | 2010 | 1 | 0.330 |
Why?
|
| Health Status Indicators | 2 | 2008 | 38 | 0.330 |
Why?
|
| Movement Disorders | 3 | 2013 | 32 | 0.320 |
Why?
|
| Patient Outcome Assessment | 3 | 2019 | 18 | 0.320 |
Why?
|
| Heterozygote | 1 | 2011 | 72 | 0.320 |
Why?
|
| Longitudinal Studies | 9 | 2023 | 651 | 0.320 |
Why?
|
| Time and Motion Studies | 2 | 2021 | 10 | 0.310 |
Why?
|
| Mutation | 1 | 2011 | 175 | 0.310 |
Why?
|
| Statistics, Nonparametric | 5 | 2013 | 72 | 0.310 |
Why?
|
| Virtual Reality | 2 | 2020 | 3 | 0.290 |
Why?
|
| Artificial Limbs | 1 | 2009 | 3 | 0.290 |
Why?
|
| Brain Injuries | 1 | 2009 | 11 | 0.290 |
Why?
|
| Prospective Studies | 6 | 2022 | 817 | 0.280 |
Why?
|
| Neuroimaging | 3 | 2020 | 66 | 0.280 |
Why?
|
| Adolescent | 7 | 2019 | 989 | 0.280 |
Why?
|
| Smartphone | 2 | 2019 | 7 | 0.270 |
Why?
|
| Exercise Tolerance | 2 | 2007 | 16 | 0.270 |
Why?
|
| Chronic Pain | 2 | 2019 | 63 | 0.270 |
Why?
|
| Electroencephalography | 4 | 2022 | 32 | 0.270 |
Why?
|
| Knee Joint | 3 | 2019 | 284 | 0.250 |
Why?
|
| Memory | 4 | 2019 | 112 | 0.250 |
Why?
|
| Electrocardiography | 5 | 2010 | 47 | 0.240 |
Why?
|
| Analysis of Variance | 4 | 2010 | 125 | 0.240 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2016 | 73 | 0.240 |
Why?
|
| Basal Ganglia | 3 | 2020 | 6 | 0.230 |
Why?
|
| Range of Motion, Articular | 2 | 2019 | 278 | 0.220 |
Why?
|
| Neural Pathways | 2 | 2016 | 23 | 0.220 |
Why?
|
| Acoustic Stimulation | 3 | 2018 | 18 | 0.210 |
Why?
|
| Linear Models | 2 | 2017 | 115 | 0.200 |
Why?
|
| Problem Solving | 4 | 2008 | 22 | 0.200 |
Why?
|
| Motor Skills | 2 | 2018 | 32 | 0.200 |
Why?
|
| Reference Values | 7 | 2004 | 103 | 0.200 |
Why?
|
| Gray Matter | 2 | 2020 | 11 | 0.200 |
Why?
|
| Feasibility Studies | 3 | 2012 | 113 | 0.190 |
Why?
|
| Myoclonic Epilepsy, Juvenile | 1 | 2023 | 1 | 0.190 |
Why?
|
| Physical Fitness | 3 | 2004 | 23 | 0.190 |
Why?
|
| Ambulatory Care Facilities | 1 | 2023 | 23 | 0.190 |
Why?
|
| Chiropractic | 1 | 2022 | 1 | 0.190 |
Why?
|
| Risk | 3 | 2012 | 97 | 0.190 |
Why?
|
| Wrist | 1 | 2022 | 11 | 0.190 |
Why?
|
| Chorea | 1 | 2022 | 3 | 0.180 |
Why?
|
| Brain Ischemia | 1 | 2022 | 35 | 0.180 |
Why?
|
| Mobile Applications | 2 | 2019 | 20 | 0.180 |
Why?
|
| Lewy Body Disease | 1 | 2022 | 54 | 0.180 |
Why?
|
| Frailty | 1 | 2021 | 6 | 0.180 |
Why?
|
| Homeostasis | 3 | 2020 | 35 | 0.180 |
Why?
|
| Spectroscopy, Near-Infrared | 3 | 2018 | 6 | 0.170 |
Why?
|
| Minority Groups | 1 | 2001 | 40 | 0.170 |
Why?
|
| Sex Factors | 4 | 2011 | 229 | 0.170 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 546 | 0.170 |
Why?
|
| Quality of Health Care | 1 | 2001 | 40 | 0.170 |
Why?
|
| Acceleration | 3 | 2012 | 7 | 0.170 |
Why?
|
| Eye Movements | 2 | 2020 | 6 | 0.170 |
Why?
|
| Motor Cortex | 1 | 2021 | 9 | 0.170 |
Why?
|
| Boston | 4 | 2019 | 7 | 0.160 |
Why?
|
| Models, Biological | 3 | 2009 | 191 | 0.160 |
Why?
|
| Paraplegia | 2 | 1991 | 4 | 0.160 |
Why?
|
| Double-Blind Method | 3 | 2018 | 166 | 0.160 |
Why?
|
| Dopamine | 1 | 2020 | 39 | 0.160 |
Why?
|
| Ankle | 1 | 2020 | 14 | 0.160 |
Why?
|
| Neurological Rehabilitation | 1 | 2020 | 2 | 0.160 |
Why?
|
| Thalamus | 1 | 2020 | 7 | 0.160 |
Why?
|
| Age Factors | 3 | 2019 | 350 | 0.160 |
Why?
|
| Locomotion | 2 | 1998 | 8 | 0.150 |
Why?
|
| Dementia | 1 | 2022 | 236 | 0.150 |
Why?
|
| Kinetics | 2 | 2017 | 110 | 0.150 |
Why?
|
| Multitasking Behavior | 1 | 2019 | 1 | 0.150 |
Why?
|
| Evoked Potentials | 1 | 2019 | 8 | 0.150 |
Why?
|
| Cardiovascular Diseases | 1 | 2001 | 166 | 0.150 |
Why?
|
| Neurologic Examination | 3 | 2007 | 49 | 0.150 |
Why?
|
| Event-Related Potentials, P300 | 1 | 2018 | 1 | 0.140 |
Why?
|
| Health | 2 | 2017 | 4 | 0.140 |
Why?
|
| Diagnostic Techniques, Neurological | 1 | 2018 | 6 | 0.140 |
Why?
|
| Auditory Perception | 1 | 2018 | 13 | 0.140 |
Why?
|
| Sleep | 1 | 2020 | 155 | 0.140 |
Why?
|
| Child | 3 | 2007 | 614 | 0.140 |
Why?
|
| Basal Ganglia Diseases | 1 | 1998 | 1 | 0.140 |
Why?
|
| Feedback, Sensory | 1 | 2018 | 3 | 0.140 |
Why?
|
| Telemedicine | 1 | 2019 | 45 | 0.140 |
Why?
|
| Healthy Volunteers | 1 | 2018 | 20 | 0.140 |
Why?
|
| Parkinsonian Disorders | 1 | 2019 | 91 | 0.130 |
Why?
|
| Neuronal Plasticity | 1 | 2018 | 27 | 0.130 |
Why?
|
| Tai Ji | 1 | 2017 | 1 | 0.130 |
Why?
|
| Fear | 2 | 2008 | 24 | 0.130 |
Why?
|
| Comorbidity | 3 | 2009 | 209 | 0.130 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 165 | 0.130 |
Why?
|
| Foot | 1 | 2017 | 17 | 0.130 |
Why?
|
| Education | 1 | 2017 | 16 | 0.130 |
Why?
|
| Eye Movement Measurements | 1 | 2017 | 1 | 0.130 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1997 | 20 | 0.130 |
Why?
|
| Prosthesis Design | 2 | 2009 | 195 | 0.130 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 1997 | 20 | 0.130 |
Why?
|
| Patient Satisfaction | 2 | 2009 | 118 | 0.130 |
Why?
|
| United States | 4 | 2020 | 989 | 0.130 |
Why?
|
| Statistics as Topic | 3 | 2017 | 51 | 0.130 |
Why?
|
| Shoes | 1 | 2017 | 13 | 0.130 |
Why?
|
| Attitude to Health | 1 | 2017 | 55 | 0.130 |
Why?
|
| Corpus Striatum | 1 | 2017 | 42 | 0.130 |
Why?
|
| Ataxia | 1 | 2017 | 51 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1997 | 105 | 0.120 |
Why?
|
| Biomarkers | 1 | 2018 | 294 | 0.120 |
Why?
|
| Stroop Test | 1 | 2016 | 2 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2022 | 182 | 0.120 |
Why?
|
| Equipment Design | 3 | 2017 | 76 | 0.120 |
Why?
|
| Species Specificity | 1 | 2016 | 28 | 0.120 |
Why?
|
| Cognitive Reserve | 1 | 2016 | 12 | 0.120 |
Why?
|
| Cohort Studies | 5 | 2019 | 827 | 0.110 |
Why?
|
| Posture | 2 | 2012 | 20 | 0.110 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 338 | 0.110 |
Why?
|
| Atrial Natriuretic Factor | 1 | 1995 | 2 | 0.110 |
Why?
|
| Hypotension, Orthostatic | 1 | 1995 | 6 | 0.110 |
Why?
|
| Observer Variation | 2 | 2013 | 47 | 0.110 |
Why?
|
| Demography | 2 | 2005 | 37 | 0.110 |
Why?
|
| Logistic Models | 2 | 2018 | 196 | 0.110 |
Why?
|
| Phenylcarbamates | 1 | 2014 | 1 | 0.110 |
Why?
|
| Cerebellum | 2 | 2020 | 17 | 0.100 |
Why?
|
| Automation | 1 | 2014 | 5 | 0.100 |
Why?
|
| Disease Progression | 2 | 2017 | 290 | 0.100 |
Why?
|
| Neuroprotective Agents | 1 | 2014 | 24 | 0.100 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2014 | 5 | 0.100 |
Why?
|
| Discriminant Analysis | 1 | 2013 | 3 | 0.100 |
Why?
|
| Nonlinear Dynamics | 2 | 2009 | 6 | 0.100 |
Why?
|
| Video Recording | 1 | 2013 | 16 | 0.100 |
Why?
|
| Atrophy | 1 | 2013 | 29 | 0.100 |
Why?
|
| Central Nervous System | 2 | 2017 | 29 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 40 | 0.100 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 1992 | 6 | 0.090 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1992 | 8 | 0.090 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2012 | 11 | 0.090 |
Why?
|
| Image Enhancement | 1 | 2012 | 25 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2012 | 38 | 0.090 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2012 | 36 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2010 | 128 | 0.090 |
Why?
|
| Predictive Value of Tests | 2 | 2010 | 218 | 0.090 |
Why?
|
| Multivariate Analysis | 2 | 2010 | 141 | 0.090 |
Why?
|
| Program Evaluation | 1 | 2011 | 55 | 0.080 |
Why?
|
| Muscles | 1 | 1991 | 49 | 0.080 |
Why?
|
| Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 1 | 2011 | 1 | 0.080 |
Why?
|
| Genetic Markers | 1 | 2011 | 18 | 0.080 |
Why?
|
| Thinking | 1 | 2010 | 9 | 0.080 |
Why?
|
| Early Diagnosis | 1 | 2010 | 27 | 0.080 |
Why?
|
| Prognosis | 3 | 2019 | 363 | 0.080 |
Why?
|
| Electric Stimulation | 1 | 1990 | 35 | 0.080 |
Why?
|
| Musculoskeletal System | 1 | 2009 | 3 | 0.080 |
Why?
|
| Biophysical Phenomena | 1 | 2009 | 21 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 143 | 0.070 |
Why?
|
| Peroneal Nerve | 1 | 2009 | 3 | 0.070 |
Why?
|
| Israel | 1 | 2009 | 7 | 0.070 |
Why?
|
| Arthralgia | 1 | 2009 | 56 | 0.070 |
Why?
|
| Stroke Rehabilitation | 1 | 2009 | 8 | 0.070 |
Why?
|
| Gait Apraxia | 1 | 2008 | 1 | 0.070 |
Why?
|
| Adaptation, Physiological | 1 | 2009 | 29 | 0.070 |
Why?
|
| Psychological Tests | 1 | 2008 | 20 | 0.070 |
Why?
|
| Mental Recall | 1 | 2008 | 24 | 0.070 |
Why?
|
| Perception | 1 | 2009 | 42 | 0.070 |
Why?
|
| Sensitivity and Specificity | 4 | 2012 | 252 | 0.070 |
Why?
|
| Recovery of Function | 1 | 2009 | 118 | 0.070 |
Why?
|
| Nervous System Diseases | 1 | 2009 | 60 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 100 | 0.070 |
Why?
|
| Anxiety | 1 | 2008 | 73 | 0.070 |
Why?
|
| Radio Waves | 1 | 2008 | 5 | 0.070 |
Why?
|
| Pain Measurement | 2 | 2019 | 211 | 0.070 |
Why?
|
| Outpatients | 1 | 2008 | 24 | 0.070 |
Why?
|
| Functional Neuroimaging | 2 | 2018 | 3 | 0.070 |
Why?
|
| Psychophysiology | 1 | 2007 | 1 | 0.070 |
Why?
|
| Peripheral Nervous System | 1 | 2007 | 1 | 0.070 |
Why?
|
| Apraxias | 1 | 2007 | 1 | 0.070 |
Why?
|
| Gyrus Cinguli | 1 | 2007 | 3 | 0.070 |
Why?
|
| Visual Cortex | 1 | 2007 | 3 | 0.070 |
Why?
|
| Parietal Lobe | 1 | 2007 | 11 | 0.060 |
Why?
|
| Dementia, Vascular | 1 | 2007 | 19 | 0.060 |
Why?
|
| Psychotropic Drugs | 1 | 2007 | 16 | 0.060 |
Why?
|
| Verbal Behavior | 1 | 2007 | 6 | 0.060 |
Why?
|
| Visual Perception | 1 | 2007 | 14 | 0.060 |
Why?
|
| Choice Behavior | 1 | 2007 | 19 | 0.060 |
Why?
|
| Physical Endurance | 2 | 2004 | 5 | 0.060 |
Why?
|
| Psychometrics | 1 | 2006 | 95 | 0.060 |
Why?
|
| Heart Failure | 2 | 2000 | 77 | 0.060 |
Why?
|
| Anthropometry | 1 | 2005 | 20 | 0.060 |
Why?
|
| Cues | 1 | 2005 | 16 | 0.060 |
Why?
|
| Hand | 1 | 2005 | 24 | 0.060 |
Why?
|
| Mental Status Schedule | 1 | 2005 | 38 | 0.050 |
Why?
|
| Diagnostic Imaging | 1 | 2005 | 43 | 0.050 |
Why?
|
| Models, Statistical | 2 | 2003 | 60 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2003 | 105 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2017 | 42 | 0.050 |
Why?
|
| Meditation | 1 | 2004 | 11 | 0.050 |
Why?
|
| Multiple System Atrophy | 1 | 2004 | 22 | 0.050 |
Why?
|
| Computer Graphics | 1 | 2003 | 3 | 0.050 |
Why?
|
| Normal Distribution | 1 | 2003 | 2 | 0.050 |
Why?
|
| Oscillometry | 1 | 2003 | 4 | 0.050 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2003 | 132 | 0.050 |
Why?
|
| Protective Factors | 1 | 2022 | 10 | 0.050 |
Why?
|
| Receptors, CCR5 | 1 | 2022 | 12 | 0.050 |
Why?
|
| Gene Frequency | 1 | 2022 | 33 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2023 | 90 | 0.050 |
Why?
|
| ROC Curve | 2 | 2017 | 78 | 0.050 |
Why?
|
| Seizures | 1 | 2023 | 35 | 0.050 |
Why?
|
| Negotiating | 1 | 2022 | 1 | 0.050 |
Why?
|
| Prevalence | 1 | 2003 | 175 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2004 | 151 | 0.050 |
Why?
|
| Genotype | 1 | 2022 | 169 | 0.050 |
Why?
|
| Disease | 1 | 2002 | 3 | 0.040 |
Why?
|
| Massachusetts | 1 | 2001 | 8 | 0.040 |
Why?
|
| Physician's Role | 1 | 2001 | 7 | 0.040 |
Why?
|
| Frail Elderly | 1 | 2021 | 19 | 0.040 |
Why?
|
| Caregivers | 1 | 2022 | 95 | 0.040 |
Why?
|
| Research Design | 1 | 2021 | 79 | 0.040 |
Why?
|
| Connectome | 1 | 2021 | 6 | 0.040 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2020 | 2 | 0.040 |
Why?
|
| Blood Flow Velocity | 1 | 2020 | 8 | 0.040 |
Why?
|
| Mass Screening | 1 | 2001 | 86 | 0.040 |
Why?
|
| Incidence | 1 | 2021 | 338 | 0.040 |
Why?
|
| Stereotyping | 1 | 2000 | 8 | 0.040 |
Why?
|
| Self Concept | 1 | 2000 | 26 | 0.040 |
Why?
|
| Arousal | 1 | 2000 | 27 | 0.040 |
Why?
|
| Organ Size | 1 | 2020 | 41 | 0.040 |
Why?
|
| Leukocytosis | 1 | 2000 | 1 | 0.040 |
Why?
|
| Animals | 4 | 2017 | 2092 | 0.040 |
Why?
|
| Muscle Contraction | 1 | 2000 | 52 | 0.040 |
Why?
|
| Leukoencephalopathies | 1 | 2019 | 3 | 0.040 |
Why?
|
| Neutrophils | 1 | 2000 | 58 | 0.040 |
Why?
|
| Hippocampus | 1 | 2020 | 97 | 0.040 |
Why?
|
| Fitness Trackers | 1 | 2019 | 6 | 0.040 |
Why?
|
| White Matter | 1 | 2020 | 52 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 2000 | 64 | 0.040 |
Why?
|
| Device Approval | 1 | 2019 | 1 | 0.040 |
Why?
|
| Computer Security | 1 | 2019 | 3 | 0.040 |
Why?
|
| Body Height | 1 | 1999 | 8 | 0.040 |
Why?
|
| Health Services Needs and Demand | 1 | 2019 | 15 | 0.040 |
Why?
|
| Muscle Strength | 1 | 2019 | 46 | 0.040 |
Why?
|
| Random Allocation | 1 | 2018 | 59 | 0.040 |
Why?
|
| Support Vector Machine | 1 | 2018 | 3 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2018 | 44 | 0.030 |
Why?
|
| Child, Preschool | 1 | 1999 | 320 | 0.030 |
Why?
|
| Vincristine | 1 | 1997 | 15 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 1997 | 22 | 0.030 |
Why?
|
| Intelligence Tests | 1 | 2017 | 9 | 0.030 |
Why?
|
| Extremities | 1 | 2017 | 10 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2017 | 30 | 0.030 |
Why?
|
| Preventive Health Services | 1 | 2017 | 7 | 0.030 |
Why?
|
| Prednisone | 1 | 1997 | 31 | 0.030 |
Why?
|
| Survival Analysis | 1 | 1997 | 99 | 0.030 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1997 | 24 | 0.030 |
Why?
|
| Putamen | 1 | 2017 | 9 | 0.030 |
Why?
|
| Doxorubicin | 1 | 1997 | 34 | 0.030 |
Why?
|
| Pressure | 1 | 2017 | 24 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 1997 | 168 | 0.030 |
Why?
|
| Patient Selection | 1 | 2017 | 111 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 205 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2000 | 1467 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2017 | 221 | 0.030 |
Why?
|
| Vascular Resistance | 1 | 1995 | 5 | 0.030 |
Why?
|
| Norepinephrine | 1 | 1995 | 19 | 0.030 |
Why?
|
| Models, Cardiovascular | 1 | 1995 | 8 | 0.030 |
Why?
|
| Skin | 1 | 1995 | 73 | 0.030 |
Why?
|
| Genetic Code | 1 | 1994 | 1 | 0.030 |
Why?
|
| DNA Replication | 1 | 1994 | 4 | 0.030 |
Why?
|
| Morphogenesis | 1 | 1994 | 4 | 0.030 |
Why?
|
| Rivastigmine | 1 | 2014 | 1 | 0.030 |
Why?
|
| Respiration | 2 | 2004 | 15 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 55 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 1992 | 33 | 0.020 |
Why?
|
| Models, Genetic | 1 | 1992 | 20 | 0.020 |
Why?
|
| DNA | 1 | 1992 | 57 | 0.020 |
Why?
|
| Coronary Disease | 1 | 1992 | 25 | 0.020 |
Why?
|
| Systole | 2 | 2002 | 10 | 0.020 |
Why?
|
| Diastole | 2 | 2002 | 24 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2012 | 156 | 0.020 |
Why?
|
| Baltimore | 1 | 2011 | 3 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2009 | 115 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2009 | 87 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2009 | 186 | 0.020 |
Why?
|
| Mental Processes | 1 | 2006 | 7 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 84 | 0.010 |
Why?
|
| High-Frequency Ventilation | 1 | 2004 | 1 | 0.010 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2004 | 2 | 0.010 |
Why?
|
| Autonomic Nervous System | 1 | 2004 | 14 | 0.010 |
Why?
|
| Rest | 1 | 2004 | 19 | 0.010 |
Why?
|
| Age Distribution | 1 | 2004 | 25 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 45 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2004 | 46 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2004 | 34 | 0.010 |
Why?
|
| Speech Disorders | 1 | 2003 | 4 | 0.010 |
Why?
|
| Base Sequence | 2 | 1994 | 57 | 0.010 |
Why?
|
| Alabama | 1 | 2002 | 1 | 0.010 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2002 | 2 | 0.010 |
Why?
|
| Coronary Artery Disease | 1 | 2002 | 56 | 0.010 |
Why?
|
| Galvanic Skin Response | 1 | 2000 | 1 | 0.010 |
Why?
|
| Subliminal Stimulation | 1 | 2000 | 1 | 0.010 |
Why?
|
| Internal-External Control | 1 | 2000 | 7 | 0.010 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2000 | 5 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2000 | 35 | 0.010 |
Why?
|
| Health Status | 1 | 2000 | 96 | 0.010 |
Why?
|
| Length of Stay | 1 | 2000 | 126 | 0.010 |
Why?
|
| Least-Squares Analysis | 1 | 1995 | 5 | 0.010 |
Why?
|
| Supine Position | 1 | 1995 | 5 | 0.010 |
Why?
|
| Monte Carlo Method | 1 | 1995 | 24 | 0.010 |
Why?
|
| Caenorhabditis elegans | 1 | 1992 | 3 | 0.010 |
Why?
|
| Myosins | 1 | 1992 | 3 | 0.010 |
Why?
|
| Biological Evolution | 1 | 1992 | 6 | 0.010 |
Why?
|
| Introns | 1 | 1992 | 9 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1992 | 6 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1992 | 16 | 0.010 |
Why?
|
| Chickens | 1 | 1992 | 19 | 0.010 |
Why?
|
| Rats | 1 | 1992 | 407 | 0.010 |
Why?
|